

SAMPLE IDENTIFICATION

Peptide:	Tirzepatide	Date Requested:	N/A
Client:	Precision Synthetics Canada	Date Received:	Jun 3, 2026
Vendor:	Precision Synthetics Canada	Date Tested:	Jun 9, 2026
Lot Number:	N/A	Date Reported:	Jun 10, 2026

HPLC-UV PURITY & CONTENT ANALYSIS

Expected Content

20.00 mg




Fig. 1 - HPLC-UV Chromatogram at 214nm

Appearance

Appearance:	White Lyophilized Powder
Cap Color:	Blue

MASS SPECTRUM ANALYSIS




Fig. 2 - Mass spectrum

BACTERIAL ENDOTOXIN TEST (USP <85>)

Method	Result	Specification	Verdict
Kinetic LAL (USP <85>)	< 0.125 EU/mL	<= 0.125 EU/mL	PASS

Interpretation: Endotoxin not detected (0.125 EU/mL) at validated 1:16 dilution (3.0 mL reconstituted vial).

NOTES

Sample analyzed by ESI-MS (positive mode) following de-salting and 100 $\times$ dilution (Agilent 6538 UHD, data file 260615_0414.d, acquired 15-Jun-2026). The spectrum is dominated by a base peak at m/z 205.07, consistent with the sodium adduct $[M+Na]^+$ of mannitol (MW 182.08; calc. $[M+Na]^+$ 205.07). The minor ion at m/z 387.15 is consistent with the mannitol dimer adduct $[2M+Na]^+$ (calc. 387.15). Remaining low-abundance signals (m/z 267, 490, 595) are consistent with residual small-molecule/cluster background.

The characteristic multiply-charged ESI envelope expected for tirzepatide (MW 4813 Da) was not observed across the scanned range, and no corresponding deconvoluted neutral mass was detected.

Conclusion: Identity not confirmed as tirzepatide. The detectable composition is consistent with mannitol, a common bulking agent/excipient.

This Certificate of Analysis is provided for informational and research purposes only.



Digital Verification